1. Barrowcliffe TW (1988) Standardization of factors II, VII, IX and X in plasma and concentrates. Report of the ICTH subcommittee on factors VIII and IX, Brussels, July 1987. Thrombosis and Haemostasis, 59, 334–334.
2. Bertina RM & Broekmans AW (1982) Protein C concentrates for therapeutic use (letter). Lancet, 2, 1348–1348.
3. Bundesgesundheitsamt (1989) Bekanntmachung über die Zulassung und Registrierung von Arzneimitteln (Aufbereitungsmonographien für den humanmedizinischen Bereich). Vom 2. August 1989. Bundesanzeiger, 182, 4567–4575.
4. Cash JD, Owens R, Dalton R, Dalton RG & Prescott RJ (1978) Thrombogenicity of factor IX concentraces: In vitro and in vivo studies. Vox Sang., 35, 105–110.
5. Eibl J, Heimburger N, Karges HE, Horowitz B, Lundblad JL, Mozen MM, Mannucci PM, Morfini M, Morgenthaler JJ, Psziewicz D & Stephan W (1988) Ways to reduce the risk of transmission of viral infections by plasma and plasma products. A comparison of methods, their advantages and disadvantages. Vox Sang., 54, 228–245.